51 research outputs found
Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study - SUPPLEMENTAL MATERIAL
No full textSupplemental data for publication: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance stud
Case/Non-Case Analysis of the FDA Adverse Events Reporting System (FAERS) Unveils Higher Reporting Odds of Photosensitivity and Esophageal Symptoms for Sarecycline Compared to Other Tetracyclines - Supplemental Data
No full textSupplemental data to accompany publication in JAADTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV
"Memorie domestiche. Conservazione ed uso dei prodotti mediali negli spazi domestici", Unità locale Napoli - Progetto PRIN 2006 (2006-2008).
No full textMedications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study - SUPPLEMENTAL MATERIAL
No full textSupplemental data for publication: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance studyTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV
- …
